CIRM Funded Clinical Trials

A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic parkinson’s disease

Disease Area:

Parkinson's Disease

Investigator:

Howard J Federoff

Institution:

Kenai Therapeutics

CIRM Grant:

CLIN2-19068 (Pre-Active)

Award Value:

$8,000,000.00

Trial Sponsor:

Kenai Therapeutics

Trial Stage:

Phase 1

Trial Status:

Launching

Targeted Enrollment:

N/A

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.